0000000001183763

AUTHOR

Y Li

showing 13 related works from this author

Safety and efficacy of non-steroidal anti-inflammatory drugs to reduce ileus after colorectal surgery

2019

Ileus is common after elective colorectal surgery, and is associated with increased adverse events and prolonged hospital stay. The aim was to assess the role of non-steroidal anti-inflammatory drugs (NSAIDs) for reducing ileus after surgery.A prospective multicentre cohort study was delivered by an international, student- and trainee-led collaborative group. Adult patients undergoing elective colorectal resection between January and April 2018 were included. The primary outcome was time to gastrointestinal recovery, measured using a composite measure of bowel function and tolerance to oral intake. The impact of NSAIDs was explored using Cox regression analyses, including the results of a c…

Malerenal failureTime Factorsmedicine.medical_treatmentAdult; Aged; Anti-Inflammatory Agents Non-Steroidal; Elective Surgical Procedures; Female; Humans; Ileus; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Postoperative Care; Postoperative Complications; Proportional Hazards Models; Prospective Studies; Recovery of Function; Time Factors; Treatment Outcome; Colectomy; ProctectomyAnti-Inflammatory Agentscolorectal surgery; ileus; non-steroidal anti-inflammatory drugs; NSAIDSKaplan-Meier Estimate030230 surgeryTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicinePostoperative ComplicationsProspective StudiesProspective cohort studyColectomyColorectalColectomyRISKProctectomyHazard ratioAnti-Inflammatory Agents Non-SteroidalAcute kidney injuryMiddle AgedColorectal surgeryNSAIDTreatment OutcomeElective Surgical Procedures030220 oncology & carcinogenesisFemalePatient SafetyNon-SteroidalCohort studyAdultcolorectal Surgery ileus non-steroidal anti-inflammatory drugsmedicine.medical_specialtyIleusNon‐steroidal anti‐inflammatory drugs. NSAIDs. Postoperative ileus. Colorectal surgery.ACUTE KIDNEY INJURYanti-inflammatory agents03 medical and health sciencesIleusInternal medicinemedicineHumansAdverse effectAgedProportional Hazards Modelsnon-steroidal anti-inflammatory drugs - ileus - colorectal surgeryPostoperative Carebusiness.industryRecovery of Functionmedicine.diseaseSettore MED/18 - Chirurgia Generalecolorectal cancer.Surgerycolorectal surgerybusiness
researchProduct

Limits on neutral Higgs boson production in the forward region in $pp$ collisions at $\sqrt{s} = 7$ TeV

2013

Limits on the cross-section times branching fraction for neutral Higgs bosons, produced in p p collisions at root s = 7 TeV, and decaying to two tau leptons with pseudorapidities between 2.0 and 4.5, are presented. The result is based on a dataset, corresponding to an integrated luminosity of 1.0 fb(-1), collected with the LHCb detector. Candidates are identified by reconstructing final states with two muons, a muon and an electron, a muon and a hadron, or an electron and a hadron. A model independent upper limit at the 95% confidence level is set on a neutral Higgs boson cross-section times branching fraction. It varies from 8.6 pb for a Higgs boson mass of 90 GeV to 0.7 pb for a Higgs bos…

GravitacióSEARCH; MSSM; LHCHadronStandard-model Higgs boson7. Clean energy01 natural sciencesHigh Energy Physics - ExperimentSettore FIS/04 - Fisica Nucleare e SubnucleareHigh Energy Physics - Experiment (hep-ex)[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Teoria quànticaNuclear ExperimentQCBosonPhysicsHiggs physicsQuantum field theoryHiggs bosonProduction (computer science)Física nuclearLHCHadron-induced high- and super-high-energy interactions (energy > 10 GeV): Inclusive production with identified leptons photons or other nonhadronic particlesParticle Physics - ExperimentGravitationParticle physicsTeoria quàntica de campsNuclear and High Energy PhysicsFOS: Physical sciencesStandard-model Higgs bosons; Supersymmetric Higgs bosons; Hadron-induced high- and super-high-energy interactions (energy > 10 GeV): Inclusive production with identified leptons photons or other nonhadronic particlesHadronsPartícules (Física nuclear)Standard ModelSEARCH0103 physical sciences010306 general physicsLarge Hadron Collider (France and Switzerland)Standard-model Higgs bosonsMuonHadron-Hadron Scattering010308 nuclear & particles physicsBranching fractionComputer Science::Information RetrievalHadron-Hadron Scattering; Higgs physicsHigh Energy Physics::PhenomenologyGran Col·lisionador d'HadronsHiggs physicSupersymmetric Higgs bosonSupersymmetric Higgs bosonsQuantum theoryHadron-Hadron Scattering; Higgs physics; Nuclear and High Energy PhysicsHigh Energy Physics::ExperimentMSSMLepton
researchProduct

40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

2004

0303 health sciencesmedicine.medical_specialtybusiness.industryEASDEndocrinology Diabetes and MetabolismHuman physiologymedicine.disease03 medical and health sciences0302 clinical medicineDiabetes mellitusFamily medicineInternal MedicineMedicinebusiness030217 neurology & neurosurgery030304 developmental biology
researchProduct

Measurement of the Lund jet plane using charged particles in 13 TeV proton-proton collisions with the ATLAS detector

2020

The prevalence of hadronic jets at the LHC requires that a deep understanding of jet formation and structure is achieved in order to reach the highest levels of experimental and theoretical precision. There have been many measurements of jet substructure at the LHC and previous colliders, but the targeted observables mix physical effects from various origins. Based on a recent proposal to factorize physical effects, this Letter presents a double-differential cross-section measurement of the Lund jet plane using 139  fb−1 of √s=13  TeV proton-proton collision data collected with the ATLAS detector using jets with transverse momentum above 675 GeV. The measurement uses charged particles to ac…

:Kjerne- og elementærpartikkelfysikk: 431 [VDP]Protonshowers [parton]13000 GeV-cmsPhysics::Instrumentation and DetectorsHadronGeneral Physics and Astronomyjet: transverse momentumPhysical Effects01 natural sciencestransverse momentum [jet]High Energy Physics - ExperimentSubatomär fysikHigh Energy Physics - Experiment (hep-ex)Charged ParticlesSubatomic PhysicsComputingMilieux_COMPUTERSANDEDUCATIONscattering [p p][PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Parton showerNuclear ExperimentGeneralLiterature_REFERENCE(e.g.dictionariesencyclopediasglossaries)PhysicsSettore FIS/01Jet (fluid)Large Hadron ColliderDouble Differential Cross SectionsDetectorhadronic [jet]Monte Carlo [numerical calculations]ATLASTransverse Momentacharged particleCharged particlemedicine.anatomical_structureCERN LHC Coll:Nuclear and elementary particle physics: 431 [VDP]colliding beams [p p]numerical calculations: Monte CarloParticle Physics - Experimentp p: scatteringCiências Naturais::Ciências Físicas530 Physicsformation [jet]Astrophysics::High Energy Astrophysical Phenomena:Ciências Físicas [Ciências Naturais]FOS: Physical sciencesMeasurements ofLHC ATLAS High Energy Physicsjet: formation530GeneralLiterature_MISCELLANEOUSMonte Carlo Modelparton: showersNuclear physicsdifferential cross section: measuredAtlas (anatomy)Fragmentationmeasured [differential cross section]0103 physical sciencesmedicineddc:530High Energy Physicsstructure010306 general physicsATLAS CollaborationScience & Technology010308 nuclear & particles physicsComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKSFísicajet: hadronic530 Physikangular resolutionProton Proton CollisionsElementary Particles and FieldsHigh Energy Physics::ExperimentDetector EffectsHadron-hadron collisionsp p: colliding beamsMathematicsofComputing_DISCRETEMATHEMATICSacceptanceexperimental results
researchProduct

Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants

2016

Background One of the global targets for non-communicable diseases is to halt, by 2025, the rise in the age-standardised adult prevalence of diabetes at its 2010 levels. We aimed to estimate worldwide trends in diabetes, how likely it is for countries to achieve the global target, and how changes in prevalence, together with population growth and ageing, are affecting the number of adults with diabetes. Methods We pooled data from population-based studies that had collected data on diabetes through measurement of its biomarkers. We used a Bayesian hierarchical model to estimate trends in diabetes prevalence-defined as fasting plasma glucose of 7.0 mmol/L or higher, or history of diagnosis w…

MaleBlood GlucoseAdultResearch ReportSettore MED/09 - Medicina Internaglucosa sanguíneaEpidemiologyhumanosEpidemiology; prevention; public health; diabetescoste de las enfermedadesDiabetes epidemiologyGlobal HealthincidenciaWorldwide trendsdistribución por sexosAge DistributionSDG 3 - Good Health and Well-beingCost of Illnessdistribución por edadespreventionpaíses en desarrolloDiabetes MellitusPrevalenceInsulinHumansHypoglycemic AgentsinsulinaAge of OnsetSex DistributionDeveloping CountriesdiabetesVDP::Medical disciplines: 700::Clinical medical disciplines: 750Incidenceprevalenciapublic healthVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750Bayes TheoremadultoHealth Surveysinforme de investigación//purl.org/pe-repo/ocde/ford#3.02.00 [https]hipoglicemiantesencuestas de saludFemalepooled analysisteorema de Bayes
researchProduct

Search for CP violation in D (+/-) -> (KSK +/-)-K-0 and D-s(+/-) -> K-S(0)pi(+/-) decays

2014

A search for \CP violation in Cabibbo-suppressed $D^{\pm}\rightarrow K^0_{\mathrm{S}} K^{\pm}$ and $D^{\pm}_{s}\rightarrow K^0_{\mathrm{S}} \pi^{\pm}$ decays is performed using $pp$ collision data, corresponding to an integrated luminosity of 3~fb$^{-1}$, recorded by the LHCb experiment. The individual $CP$-violating asymmetries are measured to be \begin{eqnarray*} \mathcal{A}_{CP}^{D^{\pm}\rightarrow K^0_{\mathrm{S}} K^{\pm}} & = & (+0.03 \pm 0.17 \pm 0.14) \% \mathcal{A}_{CP}^{D^{\pm}_{s}\rightarrow K^0_{\mathrm{S}} \pi^{\pm}} & = & (+0.38 \pm 0.46 \pm 0.17) \%, \end{eqnarray*} assuming that $CP$ violation in the Cabibbo-favoured decays is negligible. A combination of the measured asymmet…

Nuclear and High Energy PhysicsParticle physicsSDG 16 - Peacemedia_common.quotation_subjectCP violation; Hadron-Hadron ScatteringDalitz plotLHCb - Abteilung HofmannHadrons01 natural sciencesAsymmetryNOSettore FIS/04 - Fisica Nucleare e SubnucleareNuclear physicsTEV PP COLLISIONS; PRODUCTION ASYMMETRY0103 physical sciencesCP violation hadron-hadron scatteringPiTEV PP COLLISIONS010306 general physicsLarge Hadron Collider (France and Switzerland)PRODUCTION ASYMMETRYQCmedia_commonPhysicsLuminosity (scattering theory)Hadron-Hadron Scattering010308 nuclear & particles physicshep-exSDG 16 - Peace Justice and Strong InstitutionsHigh Energy Physics::PhenomenologyGran Col·lisionador d'HadronsParticle physicsPhi meson/dk/atira/pure/sustainabledevelopmentgoals/peace_justice_and_strong_institutionsJustice and Strong InstitutionsCP violationCP violationHigh Energy Physics::ExperimentFísica nuclearFísica de partículesExperimentsParticle Physics - Experiment
researchProduct

Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: A comparative risk a…

2014

High blood pressure, blood glucose, serum cholesterol, and BMI are risk factors for cardiovascular diseases and some of these factors also increase the risk of chronic kidney disease and diabetes. We estimated mortality from cardiovascular diseases, chronic kidney disease, and diabetes that was attributable to these four cardiometabolic risk factors for all countries and regions from 1980 to 2010.

MaleSettore MED/09 - Medicina Internakidney diseaseEndocrinology Diabetes and Metabolismhumanoscoste de las enfermedadesDiseaseGlobal HealthCohort StudiesEndocrinologyCost of Illnesscardiovascular diseaseHealth TransitionRisk Factorstransición sanitariaestudios prospectivosRenal Insufficiency Chronic -- complications -- epidemiology -- mortalityevaluación de riesgosRenal InsufficiencyProspective StudiesChronicestudios de cohortesMetabolic Syndromeeducation.field_of_studydiabetesMortality rateAge Factors; Cardiovascular Diseases; Cohort Studies; Cost of Illness; Diabetes Complications; Female; Health Surveys; Humans; Male; Metabolic Syndrome X; Prospective Studies; Renal Insufficiency Chronic; Risk Assessment; Risk Factors; Sex Factors; Spatio-Temporal Analysis; Global Health; Health Transition; Internal Medicine; Endocrinology Diabetes and Metabolism; EndocrinologyMetabolic Syndrome XCardiovascular Diseases -- complications -- epidemiology -- mortalityAge FactorsCardiovascular diseaseDiabetes Mellitus chronic kidney diseaseDiabetes Complications -- epidemiology -- mortalitySciences bio-médicales et agricolesDiabetes and MetabolismCardiovascular Diseasesencuestas de saludFemaleanálisis temporoespacialRisk assessmentcomplicaciones de la diabetesinsuficiencia renalmedicine.medical_specialtyCardiovascular disease; kidney disease; diabetes mortalityPopulationenfermedades cardiovascularesMetabolic Syndrome X -- complications -- epidemiology -- mortalityRisk AssessmentArticleDiabetes ComplicationsSex FactorsSpatio-Temporal Analysiscardiovascular disease; chronic kidney disease; diabetes; mortalityInternal medicineEnvironmental healthDiabetes mellitusmedicineAge Factors; Cardiovascular Diseases; Cohort Studies; Cost of Illness; Diabetes Complications; Female; Health Surveys; Humans; Male; Metabolic Syndrome X; Prospective Studies; Renal Insufficiency Chronic; Risk Assessment; Risk Factors; Sex Factors; Spatio-Temporal Analysis; Global Health; Health Transition; Endocrinology Diabetes and Metabolism; Internal Medicine; EndocrinologyInternal Medicinefactores de riesgoHumansRisk factorRenal Insufficiency Chroniceducationbusiness.industrydiabetes mortalitymedicine.diseasemortalityHealth SurveysEndocrinologyRelative riskAge Factors; Cardiovascular Diseases/complications; Cardiovascular Diseases/epidemiology; Cardiovascular Diseases/mortality; Cohort Studies; Cost of Illness; Diabetes Complications/epidemiology; Diabetes Complications/mortality; Female; Global Health; Health Surveys; Health Transition; Humans; Male; Metabolic Syndrome X/complications; Metabolic Syndrome X/epidemiology; Metabolic Syndrome X/mortality; Prospective Studies; Renal Insufficiency Chronic/complications; Renal Insufficiency Chronic/epidemiology; Renal Insufficiency Chronic/mortality; Risk Assessment; Risk Factors; Sex Factors; Spatio-Temporal Analysisbusinesschronic kidney diseaseKidney diseaseThe Lancet Diabetes and Endocrinology
researchProduct

Measurement of polarization amplitudes and CP asymmetries in B 0 → Φk *(892)0

2014

An angular analysis of the decay $B^0 \to \phi K^*(892)^0$ is reported based on a $pp$ collision data sample, corresponding to an integrated luminosity of 1.0 fb$^{-1}$, collected at a centre-of-mass energy of $\sqrt{s} = 7$ TeV with the LHCb detector. The P-wave amplitudes and phases are measured with a greater precision than by previous experiments, and confirm about equal amounts of longitudinal and transverse polarization. The S-wave $K^+ \pi^-$ and $K^+K^-$ contributions are taken into account and found to be significant. A comparison of the $B^0 \to \phi K^*(892)^0$ and $\bar{B}^0 \to \phi \bar{K}^*(892)^0$ results shows no evidence for direct CP violation in the rate asymmetry, in th…

B physic12.15.MmB physicsLuminosityHigh Energy Physics - ExperimentSettore FIS/04 - Fisica Nucleare e SubnucleareNeutral current13.88.+ePolarization[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]TOOLmedia_commonPhysicsPhysicsPHYSICS PARTICLES & FIELDSParticle physicsCharge conjugation parity time reversal and other discrete symmetriePolarization (waves)Transverse planeAmplitudeCP violationPhysical SciencesCP violationFísica nuclearLHCParticle Physics - ExperimentParticle physicsNuclear and High Energy Physicsmedia_common.quotation_subject14.40.NdFlavour Changing Neutral CurrentsLHCb - Abteilung HofmannHadronsAsymmetryDECAYSHadronic decays of bottom mesonDISTRIBUTIONSLarge Hadron Collider (France and Switzerland)B physics; CP violation; Flavour Changing Neutral Currents; Hadron-Hadron Scattering; Polarization; Nuclear and High Energy PhysicsScience & TechnologyFlavour Changing Neutral CurrentHadron-Hadron ScatteringB physics; CP violation; Flavour Changing Neutral Currents; Hadron-Hadron Scattering; PolarizationGran Col·lisionador d'HadronsLHCb13.25.HwBottom mesons (|B|>0)11.30.ErHigh Energy Physics::ExperimentFísica de partículesExperimentsPolarization in interactions and scatteringEnergy (signal processing)Bar (unit)
researchProduct

Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants

2017

Background Raised blood pressure is an important risk factor for cardiovascular diseases and chronic kidney disease. We estimated worldwide trends in mean systolic and mean diastolic blood pressure, and the prevalence of, and number of people with, raised blood pressure, defined as systolic blood pressure of 140 mm Hg or higher or diastolic blood pressure of 90 mm Hg or higher. Methods For this analysis, we pooled national, subnational, or community population-based studies that had measured blood pressure in adults aged 18 years and older. We used a Bayesian hierarchical model to estimate trends from 1975 to 2015 in mean systolic and mean diastolic blood pressure, and the prevalence of rai…

presión sanguíneahypertensionSettore MED/09 - Medicina Internaunited-stateshumanosBlood Pressuresystematic analysisGlobal HealthRisk FactorsGeneral & Internal MedicinePrevalencefactores de riesgoHumanssecular trendscardiovascular risk-factorsMedicine (all)global burdenprevalenciaBayes Theoremgender-differences//purl.org/pe-repo/ocde/ford#3.02.00 [https]sodium-intakehealth examination surveyslow-incometeorema de Bayes
researchProduct

Angular analysis of charged and neutral B → Kμ + μ − decays

2014

The angular distributions of the rare decays B → K+µ+µ- and B0 → K0 <inf>a</inf>Sμ+μ- are studied with data corresponding to 3 fb-1 of integrated luminosity, collected in proton-proton collisions at 7 and 8TeV centre-of-mass energies with the LHCb detector. The angular distribution is described by two parameters, FH and the forward-backward asymmetry of the dimuon system AFB, which are determined in bins of the dimuon mass squared. The parameter F<inf>H</inf> is a measure of the contribution from (pseudo)scalar and tensor amplitudes to the decay width. The measurements of A<inf>FB</inf> and F<inf>H</inf> reported here are the most precise to d…

B physic12.15.MmB physicsSettore FIS/04 - Fisica Nucleare e SubnucleareLuminosityNeutral currentFlavor physicsMathematics::ProbabilityNuclear Experimentmedia_commonPhysicsB physics; Flavor physics; Flavour changing neutral currents; Hadron-hadron scattering; Rare decayPhysicsPHYSICS PARTICLES & FIELDSParticle physicsAmplitudePhysical SciencesFísica nuclearLHCNuclear and High Energy PhysicsParticle physicsmedia_common.quotation_subject14.40.NdScalar (mathematics)Flavour Changing Neutral CurrentsMathematics::Analysis of PDEsLHCb - Abteilung HofmannHadronsMeasure (mathematics)AsymmetryMathematics::Numerical AnalysisStandard ModelAngular distributionTheoryofComputation_ANALYSISOFALGORITHMSANDPROBLEMCOMPLEXITYLeptonic semileptonic and radiative decays of bottom mesonSDG 7 - Affordable and Clean EnergyTensorLarge Hadron Collider (France and Switzerland)Science & Technology/dk/atira/pure/sustainabledevelopmentgoals/affordable_and_clean_energyHadron-Hadron ScatteringGran Col·lisionador d'HadronsFlavour changing neutral currentLHCbRare decay13.20.HeFlavor physicBottom mesons (|B|>0)High Energy Physics::ExperimentFísica de partículesExperiments
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Measurement of the B-0 -> K*(0) e(+) e(-) branching fraction at low dilepton mass

2013

The branching fraction of the rare decay B-0 -> K*(0) e(+) e(-) in the dilepton mass region from 30 to 1000 MeV/c(2) has been measured by the LHCb experiment, using pp collision data, corresponding to an integrated luminosity of 1.0 fb(-1), at a centre-of-mass energy of 7 TeV. The decay mode B-0 -> J/psi (e(+) e(-)) K*(0) is utilized as a normalization channel. The branching fraction B(B-0 -> K*(0) e(+) e(-)) is measured to be B(B-0 -> K*(0) e(+) e(-))(30-1000 MeV/c2) = (3.1(-0.8)(-0.3)(+0.9)(+0.2) +/- 0.2) x 10(-7) where the fi rst error is statistical, the second is systematic, and the third comes from the uncertainties on the B-0 -> J/K*(0) and J/psi -> e(+) e(-) branching fractions.

Nuclear and High Energy PhysicsParticle physicsB physicModels beyond the standard modelFlavour Changing Neutral CurrentsFOS: Physical sciencesHadrons01 natural sciencesDECAYSB physicsPartícules (Física nuclear)High Energy Physics - ExperimentSettore FIS/04 - Fisica Nucleare e SubnucleareNeutral currentHigh Energy Physics - Experiment (hep-ex)Neutral currents0103 physical sciencesLeptonic semileptonic and radiative decays of bottom meson[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]TOOLDECAYS; TOOL010306 general physicsLarge Hadron Collider (France and Switzerland)QCPhysicsFlavour Changing Neutral CurrentHadron-Hadron Scattering010308 nuclear & particles physicsBranching fractionB physics; Branching fraction; Flavour Changing Neutral Currents; Hadron-Hadron Scattering; Rare decayHigh Energy Physics::PhenomenologyGran Col·lisionador d'Hadrons3. Good healthCromodinàmica quànticaFIS/01 - FISICA SPERIMENTALERare decayB physics; Branching fraction; Flavour Changing Neutral Currents; Hadron-Hadron Scattering; Rare decay; Nuclear and High Energy PhysicsBottom mesons (|B|>0); Leptonic semileptonic and radiative decays of bottom mesons; Neutral currents; Models beyond the standard modelLeptonic semileptonic and radiative decays of bottom mesonsBottom mesons (|B|>0)Branching fractionHigh Energy Physics::ExperimentFísica nuclearDECAYParticle Physics - ExperimentQuantum chromodynamics
researchProduct

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countrie…

2015

Summary Background Up-to-date evidence about levels and trends in disease and injury incidence, prevalence, and years lived with disability (YLDs) is an essential input into global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013), we estimated these quantities for acute and chronic diseases and injuries for 188 countries between 1990 and 2013. Methods Estimates were calculated for disease and injury incidence, prevalence, and YLDs using GBD 2010 methods with some important refinements. Results for incidence of acute disorders and prevalence of chronic disorders are new additions to the analysis. Key improvements include expansion to the cause an…

MaleGerontologyNutrition and DiseaseEpidemiologyyears lived with disability Global burden of disease acute and chronic diseases countriesPrevalenceDiseaseGlobal HealthMedical and Health SciencesConduct disorderOtitis-mediaCost of IllnessResidence CharacteristicsVoeding en ZiekteEpidemiologyPrevalence80 and overGlobal health2.2 Factors relating to the physical environment2.1 Biological and endogenous factorscountriesAetiologyChildAged 80 and overMedicine(all)education.field_of_studyATTENTION-DEFICIT/HYPERACTIVITY DISORDERIncidenceMortality rateIncidence (epidemiology)Pain ResearchNeglected DiseasesAlcohol dependenceGeneral MedicineMiddle AgedGlobal burden of diseaseGlobal Burden of Disease Study 2013 CollaboratorsMental HealthInfectious DiseasesAttention deficit/Hyperactivity disorderBurden of IllnessChild PreschoolAcute DiseaseFemaleLife Sciences & BiomedicineAdultmedicine.medical_specialtyAdolescentGBD 2013Populationacute and chronic diseasesYoung AdultMental-disordersAge DistributionMedicine General & InternalWeightsGeneral & Internal MedicinemedicineHumansLife ScienceDisabled PersonsSex DistributionPreschooleducationDeveloping CountriesVLAGAgedScience & Technologybusiness.industryDeveloped CountriesCutaneous LeishmaniasisInfant NewbornInfantHealth outcomesNewbornmedicine.diseaseComorbidityBrain Disordersyears lived with disabilityGood Health and Well BeingDisease injury incidence prevalence YLDs GBD 2010Chronic DiseaseWounds and Injuriesbusiness2.4 Surveillance and distributionIron-deficiencyDemography
researchProduct